An Exploratory Phase II Study to Determine the Safety, Tolerability, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults with DSM-5 Intermittent Explosive Disorder (IED)
Clinical Trial Grant
Awarded By
Azevan Pharmaceuticals, Inc.
Start Date
November 3, 2014
End Date
September 22, 2015
Awarded By
Azevan Pharmaceuticals, Inc.
Start Date
November 3, 2014
End Date
September 22, 2015